Evaluation of Lipocalin-2 and Twist expression in thyroid cancers and its relationship with epithelial mesenchymal transition |
| |
| Institution: | 1. Department of Pathology, Ankara Training and Research Hospital, Ankara, Turkey;2. Department of Biomedical Engineering, TOBB University of Economics and Technology, Ankara, Turkey;3. Department of Medical Microbiology, Gulhane Institute of Health Sciences, Ankara, Turkey;4. Department of General Surgery, Gülhane Education and Research Hospital, Ankara, Turkey;1. Department of Pathology, University of California San Diego, La Jolla, CA, United States of America;2. Health Sciences International, University of California San Diego, La Jolla, CA, United States of America;1. N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia;2. Moscow City Oncological Hospital №62, Moscow 143423, Russia;3. S. Berezin International Institute of Biological Systems, Saint-Petersburg 197758, Russia;4. St.-Petersburg Pediatric Medical University, St.-Petersburg 194100, Russia;5. I.I. Mechnikov North-Western Medical University, St.-Petersburg 191015, Russia;1. Evidence-Based Practice Center, Mayo Clinic, Rochester, USA;2. Department of Laboratory Medicine and pathology, Mayo Clinic, Rochester, USA;1. Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand;2. Division of Pathology, Thammasat University Hospital, Pathumthani, Thailand;3. Department of Pathology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand |
| |
| Abstract: | ObjectiveTo evaluate the expressions of lipocalin-2 (LCN-2) and Twist in thyroid cancers and examine its relationship with epithelial-to-mesenchymal transition (EMT) and clinicopathological factors.Materials and methodsThe expression of LCN-2 and Twist was immunohistochemically evaluated in a total of 249 cases, including 120 patients with papillary thyroid carcinomas (PTC), 34 with follicular thyroid carcinoma (FTC), 15 with medullary thyroid carcinomas (MTC), 20 with non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), 47 with follicular adenomas (FA), and 13 with nodular hyperplasia (NH). In addition, the relationship between the expression of EMT markers E-cadherin and vimentin was investigated in malignant cases.ResultsA significant increase was observed in the LCN-2 and Twist expression from NH and FA to NIFTP, MTC, FTC, and PTC (p = 0.001). A high degree of LCN-2 expression was observed in the aggressive variants of PTC (p = 0.002). Twisthigh positivity was significantly higher in cases with the EMT-positive mesenchymal phenotype (p = 0.036).ConclusionsLCN-2 and Twist can be helpful diagnostic markers in the differentiation of benign and malignant thyroid nodules. Twisthigh expression supports the EMT process in thyroid cancer. LCN-2 and Twist expression may also serve as valuable predictive biomarkers in patients with thyroid cancer. In future, the determination of a LCN-2high expression in the aggressive variants of PTC may be integrated into targeted treatment strategies. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
